Information for patients on new weight loss drug tirzepatide

At the end of 2024, a new weight loss drug called tirzepatide was approved for use on the NHS by the National Institute for Health and Care Excellence (NICE).

Tirzepatide, which is often distributed under the brand name of Mounjaro, can help to promote weight loss when used by patients alongside a calorie-controlled diet and a more active daily lifestyle.

More details on NICE’s decision to approve this treatment for NHS use can be found here.

Tirzepatide will become available on NHS prescriptions from June 2025. However, the rollout of the treatment will be phased, and happen in increments over a number of years.  

At first, only those patients who meet a specific eligibility criteria will be able to access the drug. Over time, this criteria may be widened to allow more patients to access the treatment.

However, until such a time is confirmed, patients are kindly asked to refrain from contacting their GP practice with requests for this weight loss treatment.

We are working with GPs and other clinical colleagues to make sure that the training and education is in place to ensure that any new weight-loss medications can be safely prescribed with the right support in place for patients.

It is important to understand that tirzepatide is most effective when used in conjunction with healthy lifestyle choices, particularly those which involve diet and exercise.

With this in mind, all patients, including those who are eligible for the new drug, will still be encouraged to access NHS-supported healthy living initiatives, such as diet support and activity groups, as part of their overall weight loss journey.

Patients who do not commit to adopting a more healthy lifestyle may be refused treatment.  

We will make more information about access to tirzepatide available over the coming months so please do check back for updates.

Alternatively, further details can be found from the list of frequently asked questions.